Compare Roblox Corp (RBLX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Repligen Corporation Common Stock — how do they compare? Roblox Corp trades at $46.79 (market cap $35.37B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Roblox Corp is far larger — about 3.2× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roblox Corp for 94 Days and Repligen Corporation Common Stock for 0 Days on average.
| RBLX | RGEN | |
|---|---|---|
Market Cap | $35.37B | $11.14B |
Volume | 6,569,814 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $138.56 | $194.57 |
52-Week Low | $35.54 | $102.87 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $34.19B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox (RBLX) trades at $47.54, down 4.13% today amid mixed technical signals and analyst concerns about bookings growth. The stock shows strong revenue growth (2025: $4.89B, up 36% year-over-year) but remains unprofitable with a -17.61% net margin. Recent technical analysis indicates bullish moving averages but neutral oscillators, with key resistance at $50-$52. The company continues to beat earnings expectations, with Q2 2026 EPS of -$0.26 beating estimates by 24%.
Investment outlook balances strong user engagement and AI-driven creator tools against persistent profitability challenges. Analyst consensus sits at $51.35 with 42% buy ratings, though recent Jefferies downgrade to Underperform highlights concerns about valuation sustainability. Key risks include decelerating bookings growth and high P/B ratio of 232.69, while opportunities lie in AI-powered platform expansion and $3 billion buyback program.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
